Aptar Pharma will be showcasing its PureHale device, a new portable drug delivery device designed for upper respiratory care, at at CPhI Worldwide stand 4D10. Aptar Pharma will also introduce a range of new connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes, including gamma-sterilized drug delivery components to reduce bioburden.

Aptar is also launching its Support Services initiative, a portfolio of stage-specific development packages to help customers advance products from molecule to market.

“Through a wide range of consulting and services, Aptar Pharma innovates around delivery routes, effective drug delivery, testing and regulatory requirements with partners ranging from small-scale R&D firms to the largest international pharmaceutical companies. We look forward to launching our Support Services initiative at CPhI, and working with our customers to meet their development needs.”

Guillaume Brouet, vice president Analytical, Regulatory and Scientific Affairs at Aptar Pharma, said, “Along with showcasing its range of innovative drug delivery devices that address nasal, pulmonary, eye care, injectables and dermal drug delivery routes at Aptar Pharma’s exhibit stand, the company will also be sharing various new solutions in prescription and over-the- counter treatments.”